Skip to content

Usefulness of kestose in patients with hepatitis B

Study on the usefulness of kestose in patients with hepatitis B

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs041230162
Enrollment
40
Registered
2024-03-05
Start date
2024-03-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B hepatitis B

Interventions

Sponsors

Takashi Honda
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed as chronic hepatitis B with HBeAg negative

Exclusion criteria

Exclusion criteria: 1.Women with pregnancy or possible pregnancy 2.Patients with severe renal failure and heart failure 3.Patient who is considered to be inappropriate for entry into the trial by the investigator 4.Medical doctors decided the patients are inappropriate. 5.Patients with substantial alcohol consumption (20g/day for women or >30g/day for men). 6.Patients with poor glycemic control (HbA1c>9.0%) 7.Patients with other active hepatitis and hepatocellular carcinoma 8.Patients with history of gastrointestinal surgery 9.Patients who take nonabsorbable antibiotic

Design outcomes

Primary

MeasureTime frame
Improvement of hepatitis B virus-related markers (HBs antigen levels)

Secondary

MeasureTime frame
1.Improvement of hepatitis B virus-related markers (HBV DNA level, HBV core related antigen level) 2.Changes of short-chain fatty acid (Butyric acid, Acetic acid, Propionic acid etc.) 3.Changes of gut microbiome in feces 4.Metabolites in feces (metabolome and protein analysis) 6.Changes of bile acid in blood and feces 7.Changes of cytokine and chemokine 7.Changes of fibrosis markers 8.Changes of body weight and BMI

Contacts

Public ContactHonda Takashi

Nagoya University Hospital

honda@med.nagoya-u.ac.jp+81-52-744-2169

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026